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Atherosclerosis constitutes the underlying disease to the clinical manifestations ofmyocardial infarction, stroke, and gangrene. Despite the success
of statins, prevention of clinical events of atherosclerosis remains a major challenge in current-day cardiology. Research into the inflammatory
nature of atherosclerosis has led to improved mechanistic understanding of its pathogenesis and to the identification of novel therapeutic
targets discussed in this review. Recent genetic and epidemiological data document shared pathologies of chronic inflammatory diseases and ather-
osclerosis. Anti-inflammatory treatment regimens used in these diseases, including tumor necrosis factor-a blockade, IL-1 receptor antagonism,
and leukotriene blockademay be beneficial also in patients with coronary artery disease. Enhancing inherent atheroprotective immunity by expan-
sionof regulatoryT cellsmayemerge as a future therapeutic strategy. Immunization strategies directed against atherosclerosis-related antigens such
as epitopes within the low-density lipoprotein particle have been extensively studied in animal models and may enter the clinical stage. Success of
these novel therapies will be critically dependent on the adequate identification of patients and choice of appropriate clinical endpoints.
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Background
Cardiovascular disease represents the main cause of death and
morbidity in the western world and is projected to be the
number one killer globally by 2020.1 Cardiovascular medicine
faces a need for effective prevention of myocardial infarction,
stroke, and gangrene, which constitute the clinical manifestations
of atherosclerosis. Currently, 70% of clinical events cannot be pre-
vented with available drug therapy including statins2 and at least
10% of coronary events occur in apparently healthy individuals in
the absence of major traditional risk factors.3 Better therapeutic
opportunities are also needed to limit the extent of damage
inflicted on the heart once acute ischemia has occurred, in order
to prevent ensuing congestive heart failure (CHF).
Atherosclerosis is a chronic
inflammatory disease: clinical
evidence
Recent epidemiological studies demonstrate a significant link between
coronary artery disease (CAD) and chronic inflammatory diseases.
An increased incidence of myocardial infarction was found in patients
diagnosed with rheumatoid arthritis (RA),4 systemic lupus erythema-
tosus,5 psoriasis,6 and gout.7 The discovery of an association between
a polymorphism in the promoter of the MHC class II transactivator
and increased susceptibility to RA, multiple sclerosis and myocardial
infarction8 provides evidence for a shared immune-mediated patho-
physiology in CAD and chronic inflammatory diseases. Expression
ofMHCclass IImolecules is induced by the proinflammatory cytokine
interferon-g on several cell types such as macrophages, endothelial
cells, and smoothmuscle cells and is a prerequisite for antigen presen-
tation and activation of T cells.
Several other genetic variants with known biological functions in
inflammation and atherosclerosis were also reported to be associ-
ated with myocardial infarction. The products of these genes are
involved in adaptive immunity, such as the tumor necrosis super-
family member OX40 ligand (TNFSF4)9 that promotes T cell acti-
vation. Mediators of innate immunity comprise interleukin (IL)-1
beta,10 the cytokine lymphotoxin-a (LTA)11 and components of
the leukotriene biosynthesis pathway including arachidonate
5-lipoxygenase (ALOX5), arachidonate 5-lipoxygenase-activating
protein (ALOX5AP), and leukotriene A4 hydrolase (LTA4H).12–14
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Research on chronic inflammatory diseases has pinpointed
members of the tumor necrosis factor superfamily (TNFSF) (signa-
ture cytokine: TNF-a, signature cell-type: T lymphocyte)15 and the
IL-1 family (signature cytokine: IL-1b, signature cell type: mono-
cyte) as key mediators.16 Chronic inflammatory diseases are now
categorized into autoimmune diseases centred around the
TNFSF and autoinflammatory diseases characterized by a clinical
response to IL-1b antagonism, respectively.16 Prominent examples
of autoinflammatory diseases are gout and type 2 diabetes melli-
tus.16 Coronary artery disease appears to share features of both,
autoimmune and autoinflammatory diseases. In CAD patients pre-
senting with acute myocardial infarction, elevated blood levels of
soluble and cell-bound members of the TNFSF (TNF-a, CD40L,
LIGHT, RANKL, OPG, TRAIL)17–22 as well as from the IL-1
family (IL-1b, IL-18 and IL-33)23–25 were detected and correlated
with the subsequent risk of cardiovascular death or CHF. Soluble
members of the TNFSF and IL-1 family are also present in stable
CAD patients.26,27 Several other inflammatory mediators down-
stream of the TNF and IL-1 superfamilies were shown to contrib-
ute in the pathogenesis of atherosclerosis.28 A full list of
abbreviations can be found in the online supplementary data.
Clinical settings and
anti-inflammatory treatment
options in atherosclerosis
The dismal results of clinical trials aimed at inhibiting inflam-
mation during reperfusion injury in a non-selective manner
(steroids)29 or by targeting neutrophil recruitment30 suggest
placing the focus on a different time point. Coronary artery
disease patients at high risk for future coronary events despite
currently available treatments and evidence of vascular inflam-
mation constitute the most promising study population for
novel anti-inflammatory therapies with respect to sample size
and tolerated side effects, placing post-ACS patients at centre-
stage. Indeed, a trial termed Cardiovascular Inflammation
Reduction Trial (CIRT) has recently been designed. It will
compare the immunosuppressive drug methotrexate at very
low dose against placebo in addition to the standard treatment
in secondary prevention patients.31 In such trials, cardiovascular
death should be the prime endpoint to move the field forward,
complemented by biomarkers modifiable by anti-inflammatory
therapies and vascular imaging for adequate patient identification
and therapeutic monitoring. Figure 1 shows potential therapeutic
strategies and time points during the evolution of atherosclerosis.
Successful novel therapies will need to target inflammation
directly without interfering with the cardiovascular risk profile
(i.e. lipids) and have an acceptable safety profile. In light of the
pathogenetic similarities between CAD and many autoimmune
and autoinflammatory diseases, clinical trials conducted with
novel immunomodulatory compounds should include registration
of cardiovascular endpoints including traditional risk profiles for
post hoc analysis. One such example may be the immunomodula-
tory agent fingolimod (FTY720) for treatment of patients with
multiple sclerosis32 as experimental data on the role of FTY720
in atherosclerosis were dependent on the model and experimen-
tal conditions used.33–35
Figure 1 Emerging anti-inflammatory therapies in clinical atherosclerosis. Anti-inflammatory treatment options are shown for the distinct
stages in the development of clinical atherosclerosis.
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Statins
Statins constitute the best characterized anti-inflammatory class of
drugs in primary and secondary prevention of CAD. Beyond their
lipid-lowering activity, statins also exert anti-inflammatory effects.36
Clinical evidence for a direct anti-inflammatory effect of statins
comes from the post hoc C-reactive protein substudies of the
PROVE-IT TIMI 22, A to Z, and REVERSAL trials37–39 document-
ing that statin-induced reductions of C-reactive protein and LDL
cholesterol levels were only weakly correlated, whereas the
decrease in C-reactive protein was significantly correlated with
reduced atherosclerosis progression, independent of LDL
cholesterol-lowering. The JUPITER trial prospectively confirmed
these findings in primary prevention of individuals with elevated C-
reactive protein but with low LDL cholesterol.40 Further analysis
scheduled a priori within the JUPITER trial showed that the magni-
tude of the decrease in C-reactive protein paralleled the magnitude
of clinical benefit41 suggesting a beneficial role of targeting inflam-
mation per se in the prevention of cardiovascular events. In
addition, the Armyda trial showed that administration of high-dose
statins prior to revascularization in ACS patients reduced major
adverse cardiovascular events.42
Tumor necrosis factor-a blockade
Tumor necrosis factor blockade has shown efficacy in autoimmune
diseases43 and reduced the incidence of cardiovascular events in
RA patients, suggesting that attenuated TNF signaling reduces
not only RA but also atherosclerosis.44 Long-term safety of TNF
blockade was documented in RA patients, with no adverse effect
on the disease-inherent development of CHF,45 adding information
to previous reports on CHF patients without RA which showed no
adverse effect on hospitalization rates and mortality.46 The effects
of TNF blockade on plasma lipids require further study.47,48
A common feature of TNF antagonists is that they reduce cellular-
ity in inflamed tissues and inhibit expression of pro-inflammatory
cytokines and chemokines in addition to TNF-a (IL-1b, IL-6,
IL-8, MCP-1, GM-CSF, VEGF). Furthermore, they dampen the
TNF-a-driven production of matrix-degrading enzymes MMP-1
and MMP-3.49 These enzymes are considered to be contributing
factors to plaque instability.50 Tumour necrosis factor antagonism
normalized levels of circulating OPG and RANKL in RA patients51,
suggesting an option for therapeutic monitoring. Recent data show
that OPG administration can stabilize atherosclerotic plaques in
mice.52 OPG probably exerts this effect due to its capacity to
inhibit RANKL signalling; the latter molecule promotes protease
activity and inhibits matrix formation. The pleiotropic cytokine
IL-6 acts as a major inducer of the acute-phase response (i.e. C-
reactive protein) and impacts on the function of diverse inflamma-
tory and vascular cells. Inhibition of the IL-6 receptor recently
shown to be an effective therapeutic in RA patients, however,
was associated with elevated lipid levels.53
Interleukin-1 receptor antagonism
Interleukin-1 receptor antagonism (IL-1Ra) has shown beneficial
effects in several autoinflammatory diseases16 and recently also
stroke.54 Genetic evidence in a prospective patient cohort documen-
ted a significant correlation between a variant in the IL1-Ra gene and
carotid atherosclerosis.55 Experimental data56 provided the rationale
to conduct clinical trials on the effects of IL-1Ra to prevent post-
infarction remodeling (clinicaltrials.gov NCT00789724) and on
inflammatory biomarkers in NSTEMI patients, respectively.57
Leukotrienes
Leukotrienes belong to the family of eicosanoids and constitute
potent pro-inflammatory and smooth muscle constrictive lipid
mediators.58 Activation of the 5-lipoxygenase pathway in patients
with acute myocardial infarction was already documented in
1992.59 Recent genetic evidence linked polymorphisms in several
enzymes of the leukotriene biosynthesis pathways with myocardial
infarction comprising ALOX5, ALOX5AP, and LTA4H.12–14
Expression of leukotrienes were detected in atherosclerotic
plaques and correlated with symptoms of plaque instability.60,61
An ongoing trial aims to evaluate the role of cysteinyl-leukotriene
blockade on peripheral endothelial function by administering mon-
telukast to patients after an acute coronary event (clinicaltrials.gov
NCT00351364). A recent clinical study showed a marked
reduction in inflammatory biomarkers after administration of an
inhibitor of the 5-lipoxygenase activating protein (FLAP) to
patients carrying at-risk variants in the FLAP gene or the LTA4H
gene.62 It remains to be determined whether this tailored
therapy translates into a reduction in coronary events.
Leukocyte diversity
The concept of inherent atheroprotective immunity63 has paved
the way for therapeutic efforts to attenuate atherosclerosis.
Increasing experimental evidence documents a role for several
types of leukocytes in atherogenesis, including both pro- and anti-
inflammatory subtypes (Figure 2). Circulating monocytes and tissue
macrophages can be subdivided into ‘inflammatory’/‘classical’ and
‘resident’/‘non-classical’ subtypes based on the expression of che-
mokine and adhesion molecule receptors.64 These differences
may offer possibilities for selectively blocking entry of inflamma-
tory monocytes into atherosclerotic lesions and modify plaque
composition. The heterogeneity of T lymphocytes reflects their
diverse functions in orchestrating adaptive immune reactions.
Four types of CD4þ T helper (Th) cells have currently been ident-
ified: Th1, Th2, Th17 cells, and the regulatory T (Treg) cell lineage.
Identifying the role of the distinct effector CD4þ T cell subsets in
atherosclerosis has been of central interest in recent years.65
Recent data identified lymphoid tissue in the adventitia as an
additional site to secondary lymphoid tissue (lymph nodes)
where naı¨ve T helper (Th0) cells may become activated through
the process of antigen presentation and co-stimulation.66,67
Expansion of regulatory T cells
A deficiency in Treg cells in terms of number and/or function was
shown in patients with a variety of autoimmune diseases that led to
the concept that expansion of these cells may attenuate disease
activity. Reduced numbers were reported in blood from ACS
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patients68 and Treg cells were detected in all stages of athero-
sclerotic lesions.69 Expansion of the Treg cell pool can be achieved
either by promoting Treg cell development and survival in vivo by
administering drugs or by adoptive transfer of Treg cells following
ex vivo expansion.
Drugs designed to target surface molecules on T cells selectively
deplete activated effector T cells while promoting Treg cell expan-
sion in vivo. A monoclonal antibody directed at the CD3-e chain of
T cells showed remarkable efficacy in type 1 diabetic patients70 and
reduced atherosclerosis in mice.71 A critical role was recently
identified for the co-stimulatory molecules ICOS, PD-1, OX40L,
and CD137 in Treg and cytotoxic T cell function in mice,72–75
suggesting further targets for modulation of immune homeostasis
in atherosclerosis. Targeting the CD40-CD40L pathway appears
cumbersome as treatment directed against CD40L produced
thrombosis in vivo,76 highlighting the need for characterization of
the cellular expression pattern and functional aspects of targeting
co-stimulatory molecules.
Cytokine administration in vivo may be a valid short-term strat-
egy to enhance Treg cells. Interleukin-10 and TGF-b have impor-
tant roles in Treg cell generation and function. Administration of
IL-10 was safe in phase II trials in subjects with psoriasis. TGF-b,
however, appears as a less interesting candidate due to its pleiotro-
pic effects.
Adoptive immunotherapy to rapidly increase the circulating Treg
cell pool by re-infusion of autologous Treg cells after in vitro expansion
constitutes an interesting approach. However, several hurdles have to
be overcome before translation into the clinics. A pivotal step is the
identification and isolation of Treg cells, which poses a major chal-
lenge in light of the heterogeneity of Treg cells and the absence of
a unifying surface marker. Cell-sorting for CD4þ CD25high
CD127low T cells may constitute a valid approach.77 In order to
provide a disease-specific therapy, re-infusion of antigen-specific
Treg cells directed against antigens relevant in atherosclerosis can
be achieved by in vitro expansion of isolated antigen-specific (adaptive)
Treg cells, by means of expanding natural Treg cells isolated from
patients against specific antigens in vitro or by induced expansion of
naı¨ve T cells against specific antigens under tolerable conditions in
vitro. Several protocols were shown to effectively expand Treg cells
in vitro.78 Introduction of inducible suicide genes allows the control
of potential unwanted in vivo effects such as leukaemia or generalized
immunosuppression upon re-transfer of Treg cells into the host.
Atherosclerosis-specific
immunization
Immunization has emerged as a promising therapeutic regimen
against atherosclerosis enhancing protective antibody titers, alter-
ing the balance of pro- and anti-inflammatory T cell subtypes
and expanding Treg cells. Several antigens have been identified
and investigated for immunization against atherosclerosis in
animal models using active immunization or antibody infusion.79
Among those, epitopes recognized in the LDL particle including
apolipoprotein B-100 appear most interesting from a clinical per-
spective in light of the role of LDL in the pathogenesis of athero-
sclerosis. In order to translate those findings to the clinics,
however, antigens that can be easily manufactured under good
manufacturing practice conditions and that have a reproducible
quality without the risk of contamination are mandatory.
Clearly, more research into the cellular and inflammatory com-
ponents at different stages of human CAD is needed to identify
therapeutic targets, inflammatory biomarkers, and imaging modal-
ities suitable for improved identification of patients and monitoring
of anti-inflammatory therapies. Nonetheless, the stage is set to
provide a rationale for anti-inflammatory therapies and several
clinical studies are currently underway.
Supplementary material
Supplementary material is available at European Heart Journal
online.
Figure 2 Leukocyte diversity in atherosclerosis. Circulating
monocytes, neutrophils and T cells are recruited from circulation
into the developing atherosclerotic lesion where they differen-
tiate into effector subsets exerting predominantly pro- or anti-
inflammatory effects. Subsequent to antigen-presentation in
specialised lymphoid compartments [termed 28 (lymph node)
or 38 lymphoid organs (adventitia)] naı¨ve T helper (Th0) cells
become activated and differentiate into distinct subsets: Th1,
Th2, Th17, and induced regulatory (iTreg) T cells. Mf, macro-
phages; hsps, heat shock proteins; SMC, smooth muscle cells;
DC, dendritic cells; MHC II–TCR complex, major histocompat-
ibility complex class II–T cell receptor complex.
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Acute viral pericarditis without typical electrocardiographic changes
assessed by cardiac magnetic resonance imaging
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A 59-year-old female was admitted with
tachycardia and atypical chest pain. Physical
examination was normal. The initial electro-
cardiogram (ECG) showed atrial fibrillation
with a heart rate of 140/min. Laboratory
results on admission were unremarkable
except for a markedly elevated C-reactive
protein of 180 mg/dL (normal value
,5 mg/dL). Troponin T levels on admission
and follow-up were negative. A follow-up
ECG after 4 h documented a spontaneous
conversion in sinus rhythm and normal
ST-segments. Echocardiography showed a
normal left ventricular function (ejection
fraction 60%) with no regional wall-motion
abnormalities. A small circular pericardial
effusion was noted. Additional laboratory
tests revealed an acute parvovirus B19 infec-
tion by detecting parvovirus B19-specific IgM
antibodies in the serum.
Cardiac magnetic resonance (CMR) imaging was scheduled to rule out acute myocarditis. A thickened pericardium (5.5 mm) and a
small pericardial effusion were noted at cine-imaging (Panel A). At T2-weighted imaging (Panel B), a hyperintense signal from the
thickened pericardium was noted suggesting pericardial oedema. No signs of myocardial oedema were present. Ten minutes after
contrast administration of 0.2 mmol/kg gadolinium–DTPA inversion recovery, CMR revealed bright hyperenhancement of the com-
plete pericardium (Panels C and D). No foci of delayed enhancement in the myocardium were noted.
Based on the findings at CMR, acute pericarditis was diagnosed. The patient was treated with non-steroidal anti-inflammatory medi-
cation for 4 weeks and remained asymptomatic thereafter.
This case shows that CMR is a valuable non-invasive tool in the differential diagnosis of acute chest pain even in the absence of
typical ECG changes. Based on the findings of oedema and contrast enhancement of the pericardium suggesting an acute diffuse inflam-
matory process of the pericardium, the definite diagnosis of acute pericarditis could be established. Moreover, involvement of the
myocardium in the inflammatory process could be excluded.
Panel A. Cardiac magnetic resonance image were obtained with the balanced steady-state free precession technique showing
thickened pericardium (5.5 mm, arrows) and a small pericardial effusion.
Panel B. Short-time inversion recovery T2-weighted image show also hyperintense signal from the pericardium (arrows).
Panels C and D. Contrast-enhanced phase-sensitive inversion recovery images [four-chamber view (C ) and three-chamber view (D)]
in the late phase after gadolinium injection reveal hyperenhancement from the pericardium (arrows).
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